17
Participants
Start Date
September 20, 2017
Primary Completion Date
April 10, 2023
Study Completion Date
April 10, 2023
Brentuximab Vedotin
Ascending dose cohorts. All cohorts will receive intravenous administration of study medication every 3 weeks for 21 weeks, for a total of eight doses.
Placebo
Placebo control for blinding (masking), 0.95% normal saline.
Hospital for Special Surgery, New York: Division of Rheumatology, New York
University of Pittsburgh Medical Center: Division of Rheumatology and Clinical, Pittsburgh
Georgetown University Medical Center: Division of Rheumatology, Washington D.C.
Duke University Medical Center: Division of Rheumatology and Immunology, Durham
Medical University of South Carolina: Division of Rheumatology & Immunology, Charleston
University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology, Ann Arbor
University of Texas Houston Medical School: Division of Rheumatology and Clinical Immunogenetics, Houston
UCLA Medical Center: Division of Rheumatology, Los Angeles
Collaborators (1)
Immune Tolerance Network (ITN)
NETWORK
Seagen Inc.
INDUSTRY
PPD Development, LP
INDUSTRY
Rho Federal Systems Division, Inc.
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH